An unusual variant glycophorin expressing protease-resistant M antigen encoded by the GYPB-E(2-4)-B hybrid gene.


Journal

Vox sanguinis
ISSN: 1423-0410
Titre abrégé: Vox Sang
Pays: England
ID NLM: 0413606

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 04 11 2019
revised: 05 03 2020
accepted: 18 03 2020
pubmed: 22 4 2020
medline: 3 2 2021
entrez: 22 4 2020
Statut: ppublish

Résumé

MNS is a highly polymorphic blood group comprising 49 antigens recognized by International Society of Blood Transfusion, some of which may have been generated by genomic recombination among the closely linked genes GYPA, GYPB and GYPE. The GYPE gene has an almost identical sequence to GYPA*01 allele in exon 2 (99% homology), which accounts for M antigen. We investigated an unusual glycophorin molecule with protease-resistant M antigen. Blood samples were screened by an automated blood typing system (PK7300) using bromelain-treated red blood cells (RBCs) and murine monoclonal anti-M. The M-positive RBC samples were analysed by immunoblotting using anti-M as the primary antibody. GYPA, GYPB and GYPE genes were analysed by polymerase chain reaction (PCR), cloning and sequencing using reticulocyte mRNA and genomic DNA. Serological tests and immunoblotting revealed that 103 of the 193 009 individuals (0·0534%) expressed protease-resistant M-active glycophorin having a molecular weight of 20 kDa. All the 103 individuals were S+ s- or S- s+. When reticulocyte mRNA from the individuals with M-active glycophorin (20 kDa) was examined by PCR and cloning followed by sequencing, a novel GYPE-B hybrid transcript was identified. Long-range PCR and sequencing using genomic DNA revealed that the individuals had a GYPB-E(2-4)-B hybrid gene. This hybrid gene was predicted to encode a 59-amino-acid mature glycoprotein that expresses no S or s antigens CONCLUSIONS: The prevalence of the M-active glycophorin (20 kDa) in the Japanese population is 0·0534%. This glycophorin is predicted to be a 59 amino acids polypeptide encoded by the novel GYPB-E(2-4)-B hybrid gene.

Sections du résumé

BACKGROUND AND OBJECTIVES OBJECTIVE
MNS is a highly polymorphic blood group comprising 49 antigens recognized by International Society of Blood Transfusion, some of which may have been generated by genomic recombination among the closely linked genes GYPA, GYPB and GYPE. The GYPE gene has an almost identical sequence to GYPA*01 allele in exon 2 (99% homology), which accounts for M antigen. We investigated an unusual glycophorin molecule with protease-resistant M antigen.
METHODS METHODS
Blood samples were screened by an automated blood typing system (PK7300) using bromelain-treated red blood cells (RBCs) and murine monoclonal anti-M. The M-positive RBC samples were analysed by immunoblotting using anti-M as the primary antibody. GYPA, GYPB and GYPE genes were analysed by polymerase chain reaction (PCR), cloning and sequencing using reticulocyte mRNA and genomic DNA.
RESULTS RESULTS
Serological tests and immunoblotting revealed that 103 of the 193 009 individuals (0·0534%) expressed protease-resistant M-active glycophorin having a molecular weight of 20 kDa. All the 103 individuals were S+ s- or S- s+. When reticulocyte mRNA from the individuals with M-active glycophorin (20 kDa) was examined by PCR and cloning followed by sequencing, a novel GYPE-B hybrid transcript was identified. Long-range PCR and sequencing using genomic DNA revealed that the individuals had a GYPB-E(2-4)-B hybrid gene. This hybrid gene was predicted to encode a 59-amino-acid mature glycoprotein that expresses no S or s antigens CONCLUSIONS: The prevalence of the M-active glycophorin (20 kDa) in the Japanese population is 0·0534%. This glycophorin is predicted to be a 59 amino acids polypeptide encoded by the novel GYPB-E(2-4)-B hybrid gene.

Identifiants

pubmed: 32314425
doi: 10.1111/vox.12918
doi:

Substances chimiques

GYPB protein, human 0
Glycophorins 0
RNA, Messenger 0
Peptide Hydrolases EC 3.4.-

Banques de données

GENBANK
['LC505672', 'LC505673']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

579-585

Informations de copyright

© 2020 International Society of Blood Transfusion.

Références

Anstee DJ: The nature and abundance of human red cell surface glycophorins. J Immunogenet 1990; 17:219-225
Daniels G: Human blood groups, 3rd edn. Oxford, Wiley-Blackwell, 2013:P96-161
Reid ME, Storry JR: Low-incidence MNS antigens associated with single amino acid changes and their susceptibility to enzyme treatment. Immunohematology 2001; 17:76-81
Dahr W, Uhlenbruck G, Leikola J, et al.: Studies on the membrane glycoprotein defect of En(a−) erythrocytes. III. N-terminal amino acids of sialoglycoproteins from normal and En(a−) red cells. J Immunogenet 1978; 5:117-127
Uchikawa M, Tsuneyama H, Juji T, et al.: An unusual protease resistant M antigen detected in Japanese. Vox Sang 1994; 67(Suppl 1):116
Reid ME, Lisowska E, Blanchard D: Coordinator’s report: Glycophorin/band 3 and associated antigens. Transfus Clin Biol 1997; 4:57-64
Toyoda C, Suzuki Y, Tsuneyama H, et al.: Production of human monoclonal anti-Jk3, recognizing an epitope including the Jka/Jkb polymorphic site of the Kidd glycoprotein. Transfus Med 2014; 24:286-291
Ogasawara K, Osabe T, Suzuki Y, et al.: A new ABCB2 null allele with a 27-kb deletion including the promoter region causing the Jr(a−) phenotype. Transfusion 2015; 55:1467-1471
Ogasawara K, Sasaki K, Isa K, et al.: Weak D alleles in Japanese: a 960G>A silent mutation in exon 7 of the RHD gene that affects D expression. Vox Sang 2016; 110:179-184
Willemetz A, Nataf J, Thonier V, et al.: Gene conversion events between GYPB and GYPE abolish expression of the S and s blood group antigens. Vox Sang 2015; 108:410-416

Auteurs

Hatsue Tsuneyama (H)

Japanese Red Cross Kanto-Koshinetsu Block Blood Center, Tokyo, Japan.
Japanese Red Cross Central Blood Institute, Tokyo, Japan.

Kazumi Isa (K)

Japanese Red Cross Central Blood Institute, Tokyo, Japan.

Naoko Watanabe-Okochi (N)

Japanese Red Cross Kanto-Koshinetsu Block Blood Center, Tokyo, Japan.

Kenichi Ogasawara (K)

Japanese Red Cross Central Blood Institute, Tokyo, Japan.

Makoto Uchikawa (M)

Japanese Red Cross Kanto-Koshinetsu Block Blood Center, Tokyo, Japan.

Masahiro Satake (M)

Japanese Red Cross Central Blood Institute, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH